EP2350012 - QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 04.05.2018 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 26.05.2017 | ||
Former | Grant of patent is intended Status updated on 02.02.2017 | ||
Former | Examination is in progress Status updated on 10.01.2017 | Most recent event Tooltip | 29.05.2020 | Lapse of the patent in a contracting state New state(s): PT | published on 01.07.2020 [2020/27] | Applicant(s) | For all designated states The Johns Hopkins University 3400 N. Charles Street Baltimore, MD 21218 / US | [2011/31] | Inventor(s) | 01 /
LIU, Jun, O. 6909 Sandy Creek Court Clarksville MD 21029 / US | 02 /
SHIM, Joong, Sup 4504 Lyons Run Circle Apt. 203 Owings Mills MD 21117 / US | 03 /
CHONG, Curtis, R. 501 St. Paul St. Apt. 304 Baltimore MD 21202 / US | 04 /
BHAT, Shridhar 8 Saddletop Ct. Apartment D Cockeysville MD 21030 / US | [2017/26] |
Former [2011/31] | 01 /
LIU, Jun, O. 6909 Sandy Creek Court Clarksville MD 21029 / US | ||
02 /
SHIM, Joong, Sup 4504 Lyons Run Circle Apt. 203 Owings Mills MD 21117 / US | |||
03 /
CHONG, Curtis, R. 501 St. Paul St. Apt. 304 Baltimore MD 21202 / US | |||
04 /
BHAT, Shridhar 8 Saddletop Ct. Apartment D Cockeysville MD 21030 / US | Representative(s) | Adam, Holger, et al Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | [2017/26] |
Former [2012/03] | Adam, Holger, et al Kraus & Weisert Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 80539 München / DE | ||
Former [2011/31] | Adam, Holger Kraus & Weisert Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 80539 München / DE | Application number, filing date | 09819542.3 | 06.10.2009 | [2011/31] | WO2009US05475 | Priority number, date | US20080102919P | 06.10.2008 Original published format: US 102919 P | [2011/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2010042163 | Date: | 15.04.2010 | Language: | EN | [2010/15] | Type: | A2 Application without search report | No.: | EP2350012 | Date: | 03.08.2011 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.04.2010 takes the place of the publication of the European patent application. | [2011/31] | Type: | B1 Patent specification | No.: | EP2350012 | Date: | 28.06.2017 | Language: | EN | [2017/26] | Search report(s) | International search report - published on: | KR | 10.09.2010 | (Supplementary) European search report - dispatched on: | EP | 21.09.2012 | Classification | IPC: | C07D215/28, C07D215/04, A61K31/47, A61P35/00, C07D417/14 | [2012/43] | CPC: |
C07D215/04 (EP,US);
A61K31/47 (EP,US);
A61P17/00 (EP);
A61P19/02 (EP);
A61P27/02 (EP);
A61P29/00 (EP);
A61P35/00 (EP);
A61P7/10 (EP);
C07D417/14 (EP,US);
Y02A50/30 (EP)
(-)
|
Former IPC [2011/31] | C07D215/28, C07D215/04, A61K31/47, A61P35/00 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2017/26] |
Former [2011/31] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR | Extension states | AL | Not yet paid | BA | Not yet paid | RS | Not yet paid | Title | German: | CHINOLINVERBINDUNGEN ALS ANGIOGENESE-, HUMANE METHIONINAMINOPEPTIDASE- UND SIRT1-HEMMER SOWIE VERFAHREN ZUR BEHANDLUNG VON ERKRANKUNGEN | [2011/31] | English: | QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS | [2011/31] | French: | COMPOSÉS DE QUINOLINE EN TANT QU'INHIBITEURS DE L'ANGIOGENÈSE, DE LA MÉTHIONINE AMINOPEPTIDASE HUMAINE ET DE LA SIRT1, ET MÉTHODES DE TRAITEMENT DE TROUBLES | [2011/31] | Entry into regional phase | 28.04.2011 | National basic fee paid | 28.04.2011 | Search fee paid | 28.04.2011 | Designation fee(s) paid | 28.04.2011 | Examination fee paid | Examination procedure | 28.04.2011 | Examination requested [2011/31] | 12.07.2013 | Amendment by applicant (claims and/or description) | 31.07.2013 | Despatch of a communication from the examining division (Time limit: M04) | 25.11.2013 | Reply to a communication from the examining division | 26.01.2015 | Despatch of a communication from the examining division (Time limit: M03) | 22.04.2015 | Reply to a communication from the examining division | 05.08.2015 | Despatch of a communication from the examining division (Time limit: M05) | 12.01.2016 | Reply to a communication from the examining division | 23.06.2016 | Despatch of a communication from the examining division (Time limit: M02) | 04.08.2016 | Reply to a communication from the examining division | 08.09.2016 | Communication of intention to grant the patent | 23.12.2016 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 03.02.2017 | Communication of intention to grant the patent | 12.05.2017 | Fee for grant paid | 12.05.2017 | Fee for publishing/printing paid | 12.05.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 31.07.2013 | Opposition(s) | 29.03.2018 | No opposition filed within time limit [2018/23] | Fees paid | Renewal fee | 25.10.2011 | Renewal fee patent year 03 | 25.10.2012 | Renewal fee patent year 04 | 28.10.2013 | Renewal fee patent year 05 | 27.10.2014 | Renewal fee patent year 06 | 27.10.2015 | Renewal fee patent year 07 | 27.10.2016 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 06.10.2009 | AT | 28.06.2017 | CY | 28.06.2017 | CZ | 28.06.2017 | DK | 28.06.2017 | EE | 28.06.2017 | FI | 28.06.2017 | HR | 28.06.2017 | LT | 28.06.2017 | MC | 28.06.2017 | MK | 28.06.2017 | NL | 28.06.2017 | PL | 28.06.2017 | PT | 28.06.2017 | RO | 28.06.2017 | SE | 28.06.2017 | SI | 28.06.2017 | SK | 28.06.2017 | SM | 28.06.2017 | TR | 28.06.2017 | BG | 28.09.2017 | NO | 28.09.2017 | GR | 29.09.2017 | IE | 06.10.2017 | LU | 06.10.2017 | MT | 06.10.2017 | IS | 28.10.2017 | BE | 31.10.2017 | CH | 31.10.2017 | LI | 31.10.2017 | [2020/27] |
Former [2020/15] | HU | 06.10.2009 | |
AT | 28.06.2017 | ||
CY | 28.06.2017 | ||
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
MK | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SI | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
TR | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
IE | 06.10.2017 | ||
LU | 06.10.2017 | ||
MT | 06.10.2017 | ||
IS | 28.10.2017 | ||
BE | 31.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2019/51] | HU | 06.10.2009 | |
AT | 28.06.2017 | ||
CY | 28.06.2017 | ||
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
MK | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SI | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
IE | 06.10.2017 | ||
LU | 06.10.2017 | ||
MT | 06.10.2017 | ||
IS | 28.10.2017 | ||
BE | 31.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2019/46] | HU | 06.10.2009 | |
AT | 28.06.2017 | ||
CY | 28.06.2017 | ||
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SI | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
IE | 06.10.2017 | ||
LU | 06.10.2017 | ||
MT | 06.10.2017 | ||
IS | 28.10.2017 | ||
BE | 31.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2019/31] | HU | 06.10.2009 | |
AT | 28.06.2017 | ||
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SI | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
IE | 06.10.2017 | ||
LU | 06.10.2017 | ||
MT | 06.10.2017 | ||
IS | 28.10.2017 | ||
BE | 31.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2018/45] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SI | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
IE | 06.10.2017 | ||
LU | 06.10.2017 | ||
MT | 06.10.2017 | ||
IS | 28.10.2017 | ||
BE | 31.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2018/43] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SI | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
LU | 06.10.2017 | ||
MT | 06.10.2017 | ||
IS | 28.10.2017 | ||
BE | 31.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2018/39] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SI | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
LU | 06.10.2017 | ||
IS | 28.10.2017 | ||
BE | 31.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2018/36] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
LU | 06.10.2017 | ||
IS | 28.10.2017 | ||
BE | 31.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2018/35] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
LU | 06.10.2017 | ||
IS | 28.10.2017 | ||
CH | 31.10.2017 | ||
LI | 31.10.2017 | ||
Former [2018/29] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
MC | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
IS | 28.10.2017 | ||
Former [2018/21] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
DK | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
IS | 28.10.2017 | ||
Former [2018/11] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
NL | 28.06.2017 | ||
PL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SK | 28.06.2017 | ||
SM | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
IS | 28.10.2017 | ||
Former [2018/10] | AT | 28.06.2017 | |
CZ | 28.06.2017 | ||
EE | 28.06.2017 | ||
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
NL | 28.06.2017 | ||
RO | 28.06.2017 | ||
SE | 28.06.2017 | ||
SK | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
Former [2018/09] | EE | 28.06.2017 | |
FI | 28.06.2017 | ||
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
NL | 28.06.2017 | ||
SE | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
Former [2017/52] | FI | 28.06.2017 | |
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
NL | 28.06.2017 | ||
SE | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
Former [2017/50] | FI | 28.06.2017 | |
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
SE | 28.06.2017 | ||
BG | 28.09.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | ||
Former [2017/49] | FI | 28.06.2017 | |
HR | 28.06.2017 | ||
LT | 28.06.2017 | ||
NO | 28.09.2017 | ||
GR | 29.09.2017 | Documents cited: | Search | [X]WO2007086663 (UNIV SEOUL FOUNDATION OF IND A [KR], et al) [X] 1-6,10-15 * page 5; example 7; claims 1,23-26; table 1 *; | [X]WO2006117660 (CLIO PHARMACEUTICAL CORP [US], et al) [X] 1-6,10-15 * example -; claims 1,11,15 *; | [X]WO2008013966 (UNIV JOHNS HOPKINS [US], et al) [X] 1-6,10-15 * page 3; claims 1,7 *; | [X]JPH0597674 (NIPPON MINING CO) [X] 1-6,10-15 * examples 1-3,5-10; claim 1 *; | [X]US3351525 (ERNST HODEL) [X] 1-6,10,14,15 * example - *; | [X]EP0254866 (BASF AG [DE]) [X] 1-6,10,14,15 * page 2, line 30 - line 42; example 1 * * page 7 - page 51 *; | [X]US5380852 (SCHUETZE RAINER [DE], et al) [X] 1-6,10,14,15 * column 4, line 20; claim -; table 1 *; | [E]WO2009146546 (UNIV HEALTH NETWORK [CA], et al) [E] 1-6,10-15 * claim -; table 1 * | [X] - DING WEI-QUN ET AL, "Anticancer activity of the antibiotic clioquinol", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050401), vol. 65, no. 8, doi:10.1158/0008-5472.CAN-04-4385, ISSN 0008-5472, pages 3389 - 3395, XP002371610 [X] 1-6,10-15 * page 3389 * * page 3394, column r * DOI: http://dx.doi.org/10.1158/0008-5472.CAN-04-4385 | [X] - MUSIOL ET AL, "Investigating biological activity spectrum for novel quinoline analogues", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, (20070119), vol. 15, no. 3, doi:10.1016/J.BMC.2006.11.020, ISSN 0968-0896, pages 1280 - 1288, XP005823069 [X] 1-6,10-15 * page 1284; table 1 * DOI: http://dx.doi.org/10.1016/j.bmc.2006.11.020 | [T] - SHRIDHAR BHAT ET AL, "Substituted oxines inhibit endothelial cell proliferation and angiogenesis", ORGANIC & BIOMOLECULAR CHEMISTRY, (20120101), vol. 10, no. 15, doi:10.1039/c2ob06978d, ISSN 1477-0520, page 2979, XP055037778 [T] * page 2987 - page 2988; figure 2; example - * DOI: http://dx.doi.org/10.1039/c2ob06978d | [X] - UNGUREANU M ET AL, "SYNTHESIS OF NEW ANTIBACTERIAN AND ANTIFUNGAL DERIVATIVES OF 8-HYDROXYQUINOLINE", ANALELE STIINTIFICE ALE UNIVERSITATII AL. I. CUZA DIN IASI,SECTIUNEA 1C: CHIMIE, UNIVERSITATEA AL. I. CUZA: CARTIMEX, IASI, RO, (19990101), vol. 7, no. 1, ISSN 0041-9117, pages 55 - 60, XP001053040 [X] 1-6,10-15 * page 55; example -; table 1 * | International search | [X]WO0116108 (LIGAND PHARM INC [US], et al); | [X]WO0200625 (SYNGENTA PARTICIPATIONS AG [CH], et al); | [A]WO9619458 (LIGAND PHARM INC [US]); | [A]US4758264 (HUBELE ADOLF [CH]); | [A]WO2004103998 (GLAXO GROUP LTD [GB], et al) | Examination | - "Collagenases in Human Breast Carcinoma Cell Lines", CANCER RES, (19860101), page 1349, XP055072506 | - C. PELLETIER ET AL, "Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (19950301), vol. 39, no. 3, doi:10.1128/AAC.39.3.707, ISSN 0066-4804, pages 707 - 713, XP055072467 DOI: http://dx.doi.org/10.1128/AAC.39.3.707 | - Chelation therapy for non-overload conditions, United Healthcare services, Inc., (20150105), vol. CS016.C, pages 1 - 9 | - NASULEWICZ A, "Role of copper in tumour angiogenesis-clinical implications", JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, (2004), vol. 18, pages 1 - 8 | - TREIBER C, "Clioquonol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzehimer's disease", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (20040930), vol. 279, no. 50, pages 51958 - 51964 | - FILIZ G, "The role of metals in modulating metalloprotease activity in the AD brain", EUR BIOPHYS J, (20080213), vol. 37, pages 315 - 321 | - RODRIGUEZ-MANZANEQUE J C, "Thrombospondin-1 suppresses spontaneous tumor growth", PNAS, (20010830), vol. 98, no. 22, pages 12485 - 12490 | by applicant | US3870790 | US4226859 | US4369172 | US4842866 | US5705190 | US6638534 | US5541171 | US5217720 | US6569457 | - CHANG, Y. H. ET AL., J. BIOL. CHEM., (1992), vol. 267, pages 8007 - 8011 | - LI, X.; CHANG, Y. H., PROC. NATL. ACAD SCI. U. S. A, (1995), vol. 92, pages 12357 - 12361 | - BOXEM, M. ET AL., FEBS LETT., (2004), vol. 576, pages 245 - 250 | - CUTFORTH, T.; GAUL, U., MECH. DEV., (1999), vol. 82, pages 23 - 28 | - GRIFFITH, E. C. ET AL., CHEM. BIOL., (1997), vol. 4, pages 461 - 471 | - SIN, N. ET AL., PROC. NATL. ACAD. SCI. U. S. A, (1997), vol. 94, pages 6099 - 6103 | - INGBER, D. ET AL., NATURE, (1990), vol. 348, pages 555 - 557 | - SATCHI-FAINARO, R. ET AL., CANCER CELL, (2005), vol. 7, pages 251 - 261 | - YEH, J. R. ET AL., PROC. NATL. ACAD. SCI. U. S. A, (2006), vol. 103, pages 10379 - 10384 | - FOLKMAN, J., N. ENGL. J. MED., (1971), vol. 285, pages 1182 - 1186 | - HANAHAN, D.; FOLKMAN, J., CELL, (1996), vol. 86, pages 353 - 364 | - FOLKMAN, J.; KLAGSBRUN, M., SCIENCE, (1987), vol. 235, pages 442 - 447 | - CARMELIET, P., NAT. MED., (2003), vol. 9, pages 653 - 660 | - S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, (1977), vol. 66, pages 1 - 19 | - CURTIS, R. C. ET AL., ACS CHEM. BIOL., (2007), vol. 2, pages 263 - 270 | - ZHANG, Y. ET AL., PROC. NATL. ACAD. SCI. U. S. A, (2000), vol. 97, pages 6427 - 6432 | - YEH, J. R. ET AL., PROC. NATL. ACAD. SCI. U.S.A., (2000), vol. 97, pages 12782 - 12787 | - NORTH, B. J. ET AL., MOL. CELL, (2003), vol. 11, pages 437 - 444 | - LAIN, S. ET AL., CANCER CELL, (2008), vol. 13, pages 454 - 463 | - OTA, H. ET AL., J MOL CELL CARDIOL., (2007), vol. 43, pages 571 - 579 | - POTENTE, M. ET AL., GENES DEV., (2007), vol. 21, pages 2644 - 2658 | - ALEXANDER, J. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, (1988), vol. 31, pages 318 - 322 | - BUNDGAARD, H., Design of Prodrugs, ELSEVIER, (1985), pages 1 - 92 | - BUNDGAARD, H.; NIELSEN, N. M., JOURNAL OF MEDICINAL CHEMISTRY, (1987), vol. 30, pages 451 - 454 | - BUNDGAARD, H. A, Textbook of Drug Design and Development, HARWOOD ACADEMIC PUBL., (1991), pages 113 - 191 | - DIGENIS, G. A. ET AL., Handbook of Experimental Pharmacology, (1975), vol. 28, pages 86 - 112 | - FRIIS, G. J.; BUNDGAARD, H., A Textbook of Drug Design and Development, OVERSEAS PUBL., (1996), pages 351 - 385 | - PITMAN, I. H., MEDICINAL RESEARCH REVIEWS, (1981), vol. 1, pages 189 - 214 | - HU, X. ET AL., PROC. NATL. ACAD. SCI. U.S.A., (2006), vol. 103, pages 18148 - 18153 |